Literature DB >> 2648286

Effects of inhaled metaproterenol and atropine on the pulmonary mechanics of infants with bronchopulmonary dysplasia.

L C Kao1, D J Durand, B G Nickerson.   

Abstract

We evaluated the individual and combined effects of an inhaled beta-adrenergic agent (metaproterenol) and an inhaled anticholinergic agent (atropine) on the pulmonary function of infants with bronchopulmonary dysplasia. In this randomized, double-blind study we studied 15 infants at a mean postnatal age of 15.8 weeks (range 4-28 weeks). On 4 successive days, pulmonary function tests were measured before and after a single treatment with one of the following four aerosols: placebo, metaproterenol, atropine, and combined metaproterenol and atropine. Following treatment with metaproterenol, atropine, and combined metaproterenol and atropine, airway resistance and maximal expiratory flow at functional residual capacity improved significantly when compared with baseline. Pulmonary function values returned toward baseline by 3 hours after the treatments. We found no significant differences between the effects of metaproterenol and atropine and were unable to show any synergy of the two agents.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2648286     DOI: 10.1002/ppul.1950060204

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  8 in total

1.  New aerosol delivery system for neonatal ventilator circuits.

Authors:  M L Everard; J Stammers; J G Hardy; A D Milner
Journal:  Arch Dis Child       Date:  1992-07       Impact factor: 3.791

Review 2.  The role of anticholinergic antimuscarinic bronchodilator therapy in children.

Authors:  M Silverman
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 3.  Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants.

Authors:  Geraldine Ng; Orlando da Silva; Arne Ohlsson
Journal:  Cochrane Database Syst Rev       Date:  2016-12-14

4.  Bronchopulmonary dysplasia in preterm infants: pathophysiology and management strategies.

Authors:  Carl T D'Angio; William M Maniscalco
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 5.  Updates on Functional Characterization of Bronchopulmonary Dysplasia - The Contribution of Lung Function Testing.

Authors:  Anne Greenough; Anoop Pahuja
Journal:  Front Med (Lausanne)       Date:  2015-05-29

Review 6.  Pharmacotherapy in Bronchopulmonary Dysplasia: What Is the Evidence?

Authors:  Rishika P Sakaria; Ramasubbareddy Dhanireddy
Journal:  Front Pediatr       Date:  2022-03-09       Impact factor: 3.418

7.  Inhaled bronchodilator use for infants with bronchopulmonary dysplasia.

Authors:  J L Slaughter; M R Stenger; P B Reagan; S R Jadcherla
Journal:  J Perinatol       Date:  2014-08-07       Impact factor: 2.521

Review 8.  Systematic Review of Inhaled Bronchodilator and Corticosteroid Therapies in Infants with Bronchopulmonary Dysplasia: Implications and Future Directions.

Authors:  Brian J Clouse; Sudarshan R Jadcherla; Jonathan L Slaughter
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.